Caris Life Sciences (CAI) EBITDA Margin (2024 - 2026)

Caris Life Sciences' EBITDA Margin history runs 3 years deep, the most recent figure standing at 0.26% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 8455.0% year-over-year to 0.26%; the TTM figure through Mar 2026 stood at 3.82% (up 6424.0% YoY), while the FY2025 annual figure was 8.3%, up 6008.0% from the prior year.
• EBITDA Margin was 0.26% for Q1 2026 at Caris Life Sciences, down from 28.05% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 28.05% in Q4 2025 to a low of 84.81% in Q1 2025.
• Historically, EBITDA Margin has averaged 30.8% across 3 years, with a median of 33.89% in 2025.
• The sharpest annual moves came in 2025 and 2026: EBITDA Margin jumped 2672 bps in 2025, then surged 8455 bps in 2026.
• A 3-year view of EBITDA Margin shows it stood at 28.44% in 2024, then jumped by 199 bps to 28.05% in 2025, then sank by 101 bps to 0.26% in 2026.
• The last three EBITDA Margin figures came in at 0.26% (Q1 2026), 28.05% (Q4 2025), and 11.25% (Q3 2025), per Business Quant data.